HC Wainwright Begins Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Posted by Francis Steltz on Jun 11th, 2026

Investment analysts at HC Wainwright assumed coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) in a research report issued to clients and investors on Thursday,Benzinga reports. The firm set a “buy” rating and a $45.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.33% from the company’s current price.

DMRA has been the topic of several other reports. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Wedbush assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Thursday, May 28th. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.43.

Get Our Latest Stock Report on Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $20.15 on Thursday. The business’s 50 day moving average price is $24.68 and its 200-day moving average price is $25.34. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -3.61 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $40,000. Virtu Financial LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $49,000. Two Sigma Investments LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Connective Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $100,000. Finally, Geode Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $266,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

About Damora Therapeutics, Inc. Common Stock

(Get Free Report)

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.